Sanofi tees off work on €400M 'factory of the future' in Singapore Novavax touts early data for flu-COVID combo vaccine as FDA decision looms for single shot Abbott's COVID test sales reach all-time high—and maybe for the last time, the company says Anthem hits more than 12M registered members on its Sydney app Aptinyx pauses phase 2 trial of higher dose PTSD med without explanation J&J, Endo and McKesson settle Alabama opioid litigation for $276M Dentsply Sirona pulls CEO amid declining revenues, taps former Hillrom head to lead Sutter Health locks out union nurses who staged one-day strike GlaxoSmithKline manufacturing staffers in UK vote to strike over 'derisory' pay raise offer Aiforia lines up another AI pathology approval in Europe, now for diagnosing breast cancer AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche FDA warns against relying on genetic screening tests to make prenatal diagnoses Arcturus' stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3 HHS: Urban and low-profit hospitals more likely to be sold over last 6 years Featured Story | By Fraiser Kansteiner Sanofi broke ground on the first of two Evolutive Vaccine Facilities it's standing up through a combined investment of €900 million (about $976 million). The other plant is slated to come online in France. read more |
| |
|---|
|
Top Stories By Max Bayer Novavax touted early data of its combo vaccine for the flu and COVID-19, saying the shot elicited an immune response comparable to standalone flu and COVID shots. The results come as the company is still awaiting a decision from the FDA on its EUA submission for its COVID jab. read more By Conor Hale Diagnostic sales last quarter reached a new high point going back all the way to the start of the pandemic, bringing in more than $3.3 billion worldwide. read more By Paige Minemyer The insurer also surpassed Wall Street's expectations on revenue, according to Zacks Investment Research. read more By Max Bayer Aptinyx is temporarily putting the stop sign up for the higher dose arm of a phase 2b trial testing the company's PTSD med. The 150-mg arm was slated to start up after the 50-mg was initiated, which happened in December. read more By Zoey Becker Alabama is set to get a $276 million payout from Johnson & Johnson, Endo and McKesson as part of an opioid litigation settlement. read more By Andrea Park Don Casey's termination took effect immediately, Dentsply said Tuesday, though it has yet to find a permanent replacement for the top job. read more By Dave Muoio Cedars-Sinai, Stanford Health Care and Sutter Health have each been the recipient of new activity within the past few days. Nurses and healthcare workers across the California provider organizations are all calling for higher wages and safer workplace policies. read more By Fraiser Kansteiner Eighty-six percent of GSK Unite members voted in favor of the strike, giving GSK just 48 hours to make a “much-improved offer” lest they act, the union said. Unite is angling for a pay increase more closely aligned to the local rate of inflation, which hit a 30-year high in the U.K. of 7% back in March. read more By Andrea Park Aiforia Technologies is likely feeling a sense of euphoria after racking up its third CE mark in less than a year for another of its artificial intelligence models to aid in cancer diagnoses. read more By Nick Paul Taylor AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the cusp of phase 2, AbbVie has terminated its collaboration with BioArctic, leaving a clutch of rivals such as Novartis and Roche to compete over the Parkinson’s disease opportunity. read more By Andrea Park The current genetic testing development boom has undeniably advanced the medical field by leaps and bounds—but that doesn’t mean every test’s results should be automatically taken as gospel. read more By Nick Paul Taylor How good does a COVID-19 vaccine need to be to muscle in on the market at this late stage of the game? That is the question facing Arcturus as, armed with evidence of 55% efficacy as a primary series, it gears up for booster trials of its self-amplifying COVID-19 mRNA vaccine in the West. read more By Robert King Hospitals residing in urban areas and those with lower profit margins were more likely to be sold over the past six years, new federal data show. read more |
